Docetaxel

Docetaxel 是目前在国外临床研究中出现的一款新药或疗法，主要研究方向为Non Small Cell Lung Cancer、c-MET、NSCLC (Non-small Cell Lung Cancer)、Non-Small Cell Lung Cancer。下面汇总了它当前在全球正在招募患者的研究，以及中国患者可以走的申请途径。

正在招募患者的 Docetaxel 研究

• Trilaciclib in Combination With Docetaxel for Second-Line and Beyond Treatment of Locally Advanced or Metastatic NSCLC

  II 期招募中中国NCT06929936

• Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer

  III 期招募中美国ChileColombiaMexicoNCT03678025

• A Phase I/II Study of LM-2417 in Subjects With Advanced Solid Tumours

  I 期 / II 期招募中中国NCT06682780

• Ivonescimab in Combination With Docetaxel in Advanced Non-Small Cell Lung Cancer

  III 期招募中中国NCT06928389

• Safety and Efficacy of Glumetinib Combined With Docetaxel for Injection (Albumin-bound) in Patients With Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma and Other Solid Tumors

  II 期招募中中国NCT06947291

• A Study to Learn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients With mCRPC Who Were Previously Treated With Abiraterone Acetate (Himalayas-1)

  III 期招募中美国Puerto RicoNCT07723248

• Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer

  I 期 / II 期招募中美国NCT07667400

• Thoracic Radiotherapy and Inhibition of PD-1 and LAG-3 for Locally Advanced Non-Small Cell Lung Cancer

  II 期招募中美国NCT06865339

• Carbon Ion Radiotherapy for Locally Advanced Lung Cancer in Elderly Patients

  II 期招募中中国NCT06311981

• A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors

  I 期 / II 期招募中美国澳大利亚加拿大德国NCT04895709

• Neoadjuvant Treatment Pegylated Liposomal Doxorubicin Plus Cyclophosphamide Sequential Docetaxel Plus Trastuzumab and Pertuzumab Versus Docetaxel Plus Carboplatin Combined With Trastuzumab and Pertuzumab in HER-2 Positive Breast Cancer

  III 期招募中中国NCT05159193

• Neoadjuvant Trastuzumab Deruxtecan (SHR-A1811) + Pertuzumab in HER2+ Breast Cancer

  II 期招募中中国NCT07393425

• Safety, Tolerability, and Preliminary Efficacy of BH011 in Subjects With Non-Muscle-Invasive Bladder Cancer

  I 期 / II 期招募中中国NCT06732531

• A Study Evaluating The Combination of Immunotherapy With Radiotherapy in Non-Small Cell Lung Cancer

  II 期招募中美国NCT07603856

• A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies

  II 期招募中美国澳大利亚比利时BrazilNCT07415031

• A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma

  II 期招募中美国加拿大中国GeorgiaNCT07069712

• A Study of ASP1002 in Adults for Treatment of Solid Tumors

  I 期招募中美国NCT05719558

• A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs

  I 期 / II 期招募中美国NCT06228326

• ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer

  III 期招募中比利时挪威瑞典瑞士NCT03903835

• Pharmacokinetics and Safety of Epidiferphane and Taxanes in Breast Cancer Patients

  I 期 / II 期招募中美国NCT05074290

• Trastuzumab Deruxtecan Versus Standard Neoadjuvant Treatment for HER2-positive Breast Cancer

  II 期招募中瑞典NCT05900206

• Trilaciclib in Patients With Early-Stage HR-negative Breast Cancer Receiving Adjuvant Chemotherapy

  II 期招募中中国NCT05978648

• The Management of Metastatic Neck Nodes in N2/3 Hypopharyngeal Squamous Cell Carcinoma

  不适用招募中中国NCT05494190

• A Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate Cancer

  II 期招募中美国澳大利亚Brazil加拿大NCT07287150

本页信息整理自 ClinicalTrials.gov 公开登记数据，仅供参考，不构成医疗建议；是否适合使用该药物，请以专业医生和研究团队的意见为准。